Will CAR-NK cell therapies overshadow traditional CAR-T options for the treatment of some cancers? While preliminary data for CAR-NKs point to enhanced safety and solid tumor penetration, oncologists and executives discuss the pros and cons of these two approaches to cell therapy.
In 2017, the US Food and Drug Administration approved Novartis AG’s Kymriah for the treatment of patients with acute lymphocytic leukaemia (ALL). The decision marked a sea change – Kymriah became the first of several chimeric antigen receptor (CAR) T-cell therapies to enter the cancer market.
CAR-T cell treatment involves taking T-cells from patients’ blood, enhancing them in the lab by adding a gene for a...
From a letter of intent with BIRAC sealed at BIO 2025 to supporting Immuneel’s CAR-T efforts and a study for point-of-care manufactured anti-CD19 CAR-T cell therapy, Miltenyi Biotec is moving on multiple fronts in India. The German group also expects to advance its own CAR-T candidates.
A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.
The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.
